Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
暂无分享，去创建一个
L. Dogliotti | R. Scarpa | M. Tucci | A. Berruti | C. Terrone | A. Angeli
[1] F. Saad,et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.
[2] P. Pitt,et al. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. , 2001, The Journal of clinical endocrinology and metabolism.
[3] L. Dogliotti,et al. Pamidronate administration improves the secondary hyperparathyroidism due to “Bone hunger syndrome” in a patient with osteoblastic metastases from prostate cancer , 1997, The Prostate.
[4] S. Cerutti,et al. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P). , 1997, Anticancer research.
[5] J. Simes,et al. Prostatic cancer with bone metastases: serum alkaline phosphatase (SAP) as a predictor of response and the significance of the SAP "flare". , 1990, British journal of urology.
[6] D. W. Moss,et al. Biochemical prediction of response of bone metastases to treatment. , 1988, British Journal of Cancer.